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OBJECTIVES The present study was designed as a face-to-face functional comparison of human skeletal
myoblasts (SMs) and CD133 bone marrow-derived hematopoietic progenitors in an animal
model of semichronic myocardial infarction.
BACKGROUND Compared with SMs, bone marrow-derived cells have the advantage of plasticity and might
more effectively regenerate ischemic cardiac tissue. However, few data exist on the compar-
ative efficacy of these two cell types in semichronic infarcts.
METHODS A myocardial infarction was created by coronary ligation in 32 nude rats. Ten days later, rats
received in-scar injections of human SMs, CD133 progenitors, or culture medium. Left
ventricular function was assessed before and one month after transplantation by echocardi-
ography and pressure-volume loops. Immunofluorescence, polymerase chain reaction, and in
situ hybridization were used to detect cells grafted in the hearts.
RESULTS One month after transplantation, left ventricular ejection fraction decreased by 8  4% in
controls, whereas it increased by 7 3% in CD133-grafted hearts (p 0.0015 vs. controls)
and further by 15 5% in SM-treated hearts (p 0.008 vs. controls). Systolic indices yielded
by pressure-volume loops paralleled these data. Engrafted myotubes were identified in all
SM-treated hearts by immunofluorescence, whereas in CD133-grafted hearts, few human
cells were only detected by polymerase chain reaction.
CONCLUSIONS In the setting of postinfarction scars, the transplantation of bone marrow-derived CD133
progenitors improves cardiac function, but this benefit is not superior to that afforded by
myogenic cells. (J Am Coll Cardiol 2004;44:458–63) © 2004 by the American College of
Cardiology Foundationt
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turing the past decade, a large number of experimental
tudies have demonstrated that intramyocardial transplan-
ation of skeletal myoblasts (SMs) could effectively repair an
schemically damaged heart (1), thereby setting the stage for
arly clinical trials (2). More recently, the regeneration of
See page 464
nfarcted myocardium also has been reported with the use of
one marrow-derived mononuclear cells (3–6), hematopoi-
tic progenitors (7,8), or mesenchymal stem cells (9). Most
f these studies, however, have entailed bone marrow
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Manuscript received February 16, 2004; revised manuscript received March 26,f004, accepted March 30, 2004.ransplantation at the acute stage of myocardial infarction
nd did not include outcome comparisons with other cell
ypes. Therefore, the present study was designed as a
ace-to-face functional comparison of SM and hematopoi-
tic progenitors in an animal model of semichronic myo-
ardial infarction.
ETHODS
xperimental model. Ligation of the left coronary artery
as performed in seven-week-old immunodeficient rnu/rnu
ats (Harlan France SARL, Gannat, France) (10). Ten days
ater, rats underwent a sternotomy and then were randomly
llocated to receive in-scar injections (150 l) of human
Ms (5  106, n  8), CD133 progenitors (5  105, n 
5), or culture medium (n  9). The viability of the cells
fter thawing, assessed by fluorescence-activated cell sorting
FACS) using propidium iodide exclusion, was consistently
87%. All experiments were performed in accordance with
he “Principles of Laboratory Animal Care” formulated by
he National Society for Medical Research and the “Guide
or the Care and Use of Laboratory Animals” prepared by
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solation and characterization of human SM and CD133
ells. Human SMs were obtained from a biopsy of the
astus lateralis taken during orthopedic operations and
ultured for three weeks (2). The percentage of myogenic
ells was assessed by FACS using anti-CD56 antibodies
Becton-Dickinson, Franklin Lakes, New Jersey).
Human CD133 cells were sorted from blood obtained
y leukapheresis after cytokine (granulocyte colony-forming
nit) mobilization in patients suffering from hematological
isease. CD133 progenitors were isolated using magnetic
eads coated with antibodies against CD133 (Miltenyi
iotec, Paris, France). Purified CD133 cells were charac-
erized using monoclonal antibodies (mAbs) against human
D34, CD117 (Becton-Dickinson), CXCR4 (BD Bio-
ciences Pharmingen, San Diego, California), CD62E
Santa Cruz Biotechnology Inc., Santa Cruz, California),
nd CD54 (Caltag Laboratories, Burlingame, California).
sotype-identical antibodies served as controls. Cytometric
nalyses were performed using a FACS Calibur using
ellquest computer software (Becton-Dickinson). All cells
ere frozen until implantation.
olony-forming unit assay. Freshly prepared and cryopre-
erved CD133 cells were plated in methylcellulose (Stem
ells Technologies, Meylan, France). All experiments were
erformed in quadruplicate and at three different cell
oncentrations (500, 1,000, and 2,000 CD133 cells per
late). For all the cell concentrations tested, granulocyte/
onocyte colony-forming units were obtained on day 14.
unctional assessment. Immediately before and one
onth after transplantation, we further studied left ventric-
lar (LV) function by using two-dimensional echocardiog-
aphy (10). Left ventricular ejection fraction (LVEF) was
easured by two investigators who were blinded to the
xperiment.
Pressure-volume loops were only generated one month
fter transplantation using a LV conductance catheter (Mil-
ar Instruments, Houston, Texas) and IOX software
EMKA Technologies, Paris, France). Preload-recruitable
troke work and maximal elastance were measured after
emporary occlusion of the inferior vena cava under respi-
Abbreviations and Acronyms
FACS  fluorescence-activated cell sorting
HLA  human leukocyte antigen
LVEF  left ventricular ejection fraction
LV  left ventricular
mAb  monoclonal antibody
MyHC  myosin heavy chain
pAb  polyclonal antibody
PCR  polymerase chain reaction
SM  skeletal myoblastatory arrest (10). 6mmunofluorescence. Explanted hearts were cut into
hree segments and frozen in liquid nitrogen-cooled isopen-
ane. The detection of transplanted cells was primarily based
n the presence of human-specific membrane human leu-
ocyte antigen (HLA)-class I (1:20, mAb, Immunotech,
estbrook, Maine) and nuclear lamins-A/C (1:300, mAb,
ovocastra Laboratories, Newcastle upon Tyne, United
ingdom) antigens. Thereafter, immunolabeling was per-
ormed with antibodies directed against neonatal myosin-
eavy chain (MyHC) (1:50, rabbit polyclonal antibody
pAb], provided by G. Butler-Browne, CNRS UMR7000,
aris, France), fast-MyHC antibody (1:20, mAb, Novocas-
ra), myosin-binding protein-C (1:200, pAb, provided by L.
arrier, Inserm U582, France), and caveolin-1 (1:50, pAb,
anta-Cruz). To quantify capillary density, nine sections per
eart were stained with anticaveolin-1 antibody. Images
ere processed by a DMRB microscope (Leica, Postfach,
etzlar, Germany) equipped with epifluorescence optics.
igital images were analyzed using Vision explorer software
Graftek Imaging, Austin, Texas).
luorescent in situ hybridization. Heart cryosections (4
m) were fixed in methanol, followed by a pepsin digestion
nd formamide treatment. The slides were hybridized (2 h
t 37°C) with directly fluorescence-labeled human-specific
ulticentromeric and rat-specific Y-chromosome deoxyri-
onucleic acid probes and then counterstained with 4,6-
iamidino-2-phenylindole in antifade solution (Vector Lab-
ratories, Burlingame, California).
olymerase chain reaction (PCR). Deoxyribonucleic acid
as obtained by proteinase K digestion and phenol extrac-
ion, and PCR was performed using a human-specific Alu
rimer (upstream-primer-5-ACGCCTGTAATCCCAG-
ACTT-3; downstream-primer-5TCGCCCAGGC-
GGAGTGCA-3). Amplification conditions were as fol-
ows: 95°C for 3 min followed by 30 cycles consisting of
0°C for 30 s, 58°C for 45 s, 72°C for 60 s, and followed by
n extension at 72°C for 10 min. All samples also were
mplified to detect the glyceraldehyde-3-phosphate dehy-
rogenase gene as a control for the presence of amplifiable
eoxyribonucleic acid.
tatistics. Data are expressed as mean  SEM. All anal-
ses were performed with the StatView software (SAS
nstitute, Cary, North Carolina). Statistical comparison
mong the three groups was performed using the Kruskall-
allis test. The Mann-Whitney U test with Bonferroni’s
orrection was used for post-hoc pairwise comparisons. A
alue of p  0.0167 was considered significant.
ESULTS
haracterization of the transplanted human cells. On
he day of transplantation,85% of cultured SMs expressed
D56 and desmin markers. The CD133 cell population
purity97%) co-expressed CD34 (91 3%), CD54 (82
%), and CXCR4 (73  3%), whereas only a few co-
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Stem Cells in Infarcted Myocardium July 21, 2004:458–63xpressed CD117 (14  3%) and CD62E (13  3%)
urface markers. The functional clonogenic capacities of
D133 cells were not impaired by cryopreservation be-
ause, after 14 days of plating, there was no significant
ifference in the number of granulocyte/monocyte colony-
orming units (18  1.9 and 22  3.2 in cryopreserved and
reshly prepared CD133 cells, respectively).
unctional assessment. Baseline LVEFs were not signif-
cantly different between controls (42  3%), SM-grafted

igure 1. Functional effects of CD133 and skeletal myoblast (SM) cell
entricular ejection fraction (LVEF) from baseline pretransplantation value
nd SM-treated (n  8; closed triangles) hearts. (B) Representative tracin
f (C) maximal elastance (Emax) and (D) preload-recruitable stroke work
) hearts. Note the functional improvement in 25% of CD133-grafted44 2%), and CD133 -grafted hearts (43 2%), thereby (uggesting initial ischemic injuries of similar extent. One
onth later, transplantation of either human SM or
D133 cells resulted in a superior preservation of function
s LVEF decreased from the corresponding baseline values
n controls and increased in CD133-grafted and SM-
rafted hearts (Fig. 1A). This effect was primarily the result
f a smaller increase in end-systolic volumes from baseline
alues in SM-treated (0.01  0.01 ml) and CD133-
reated hearts (0.05  0.01 ml) compared with controls
plantation. (A) Individual values and mean percentage of change in left
ntrols (n  9; open triangles), CD133-treated (n  15; closed circles),
pressure-volume occlusion loops. (C and D) Individual values and means
) in controls (n  9), CD133-grafted (n  12), and SM-grafted (n 
SM-grafted animals.*p  0.0015, †p  0.008, ‡p  0.01 vs. controls.trans
s in co
gs of
(PRSW
and0.08 0.02 ml). In contrast, LV end-diastolic volumes did
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July 21, 2004:458–63 Stem Cells in Infarcted Myocardiumot differ among the groups. Echocardiographic data were
ecorded at similar heart rates.
The improvement of systolic function in transplanted rats
as further supported by pressure-volume loops, which dem-
nstrated that maximal elastance and preload-recruitable
troke work were shifted leftward in the SM group and to a
reater extent in the CD133-grafted hearts compared with
ontrols (Figs. 1B to 1D).
henotypical characterization of transplanted cells. One
onth after transplantation, the presence of many lamins-
/C (Fig. 2A) and HLA-class I-positive human cells were
dentified in all SM-grafted hearts. Some of these cells
xpressed neonatal and adult MyHC (Figs. 2B and 2C), but
one co-expressed cardiomyocyte-specific myosin-binding
rotein-C and endothelial cell-specific caveolin-1. Con-
ersely, in the CD133-grafted hearts, human cells could
ot be detected by either immunofluorescence or by in situ
ybridization using human-specific multicentromeric probes
nd were only identified in 8 of 13 hearts by PCR using
uman-specific Alu primer (Fig. 2D).
Angiogenesis did not differ among the three groups, with
n average capillary density in the border zone of 18.3 1.3
m2, 17.8 1.2 m2, and 17.8 0.7/100 m2 in controls,
M-grafted, and CD133-grafted hearts, respectively.
ISCUSSION
he major finding of this study is that human cryopreserved
D133 progenitors and SMs both improve the preserva-
ion of postinfarction LV function compared with controls
hat receive culture medium alone. In contrast to SMs
hich, despite their functional efficacy (1) remain lineage-
igure 2. Detection of human cells in grafted rat hearts. One month after s
ositively stained for human lamins-A/C (A); some of them expressed (B)
etection via polymerase chain reaction of human cells in grafted hearts uestricted, bone marrow-derived cells have the purported tdvantage of plasticity. This finding has led to early clinical
rials (3–6) that were reported to be successful. However,
ur failure to demonstrate the benefits of mononuclear cell
ransplantation in infarcted sheep myocardium (11) has led
s to refocus on specific subpopulations. In this setting,
D133 were selected because: 1) the immaturity of these
ells should make them prone to signal-induced phenotypic
hanges (12); 2) most CD133 cells also express the CD34
urface marker, which has been associated with cardiopro-
ective properties (8); and 3) CD133 cells can be sorted by
clinically approved kit. Indeed, CD133 cells already have
een injected in postinfarction scars during coronary artery
urgery but without conclusive evidence for their functional
fficacy (13).
Although baseline LVEFs were moderately impaired
ecause the survival of nude rats was only compatible with
elatively small infarcts, treatment effects were readily ap-
arent, with the two transplanted groups demonstrating a
etter and comparable preservation of LV function com-
ared with controls. Although a robust engraftment of SM
as consistently demonstrated by the co-expression of
uman nuclear and skeletal muscle-specific markers, immu-
ofluorescence failed to identify human cells in the
D133 group. These cells could only be detected by PCR,
nd none of them expressed muscular or endothelial mark-
rs. Technical problems accounting for our negative im-
unofluoresence data are unlikely because: 1) similar anti-
odies were consistently used throughout the study and
urned out to be successful for detecting engrafted myo-
ubes; 2) even if fusion events had occurred between
D133 cells and the few residual in-scar cardiomyocytes,
l myoblast (SM) grafting, immunofluorescence shows that many cells were
tal myosin heavy chain (MyHC) (arrows) and (C) adult-fast MyHC. (D)
a human-specific Alu primer.keleta
neona
singhereby leading to loss of staining for HLA-class I antigens,
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Stem Cells in Infarcted Myocardium July 21, 2004:458–63he nuclear-bound lamins A/C should still have been
etectable in these chimeric cells; and 3) additional in situ
ybridization using human-specific multicentromeric probes
ave failed to detect polyploid cells in the CD133-grafted
earts. The reasons for the CD133 graft loss over the course
f time are unclear and could involve the greater sensitivity of
D133 cells to ischemia; the low percentage of CD34 cells,
side population credited for a higher engraftment potential
14); and/or rejection due to B lymphocytes and natural killer
ells still present in nude rats that could have affected CD133
ore than myoblasts that lack HLA-class II antigens (15).
he smaller number of injected CD133 cells compared with
M cells was primarily justified by the difference in the
roliferation rate of these two cell lineages because CD133
ells have a greater potential for multiple doublings (16). Our
hoice of cell dosing was also dictated by clinical consider-
tions. Using a bone marrow aspirate, Stamm et al. (13)
njected 2  106 CD133 cells in patients undergoing con-
omitant bypass surgery, a value only four times higher than
he dose that we have used in 1-g rat hearts. Even after
ytokine mobilization and apheresis, one is able to obtain at
ost 200 106 CD133 cells (17), which is still several orders
f magnitude lower than the one-billion value that can be
chieved with successfully expanded SMs (2). Altogether, the
ose used in this study is consistent with that which was
eported in previous studies in which murine Sca-1 cells (7),
hich are roughly equivalent to CD133 cells, or human
D34 progenitors (8) were found to successfully engraft in
nfarcted areas and induce myocardial tissue repair. However,
n these “positive” studies, cells were injected early after
nfarction and may thus have found appropriate cytokines and
rowth factors for enhancing their survival and committing
hem towards a cardiomyogenic and/or endothelial phenotype.
hese signals most likely wane when freshly ischemic tissue is
eplaced by scar tissue. As such, the present observations are
onsistent with the limited bone-marrow graft survival in a
ouse model of doxorubicin-induced cardiomyopathy (18).
hey also are in line with the recent findings that the almost
omplete lack of detectable hematopoietic stem cells (c-kit-
nriched or c-kitThy1.1loLin-Sca-1) 30 days after their
mplantation into myocardial infracted areas did not preclude
he echocardiographic demonstration of a limitation of ven-
ricular dilatation and dysfunction in the transplanted mice
19).
The discrepancy between the robust engraftment of SMs
nd the scarcity of remaining progenitors suggests different
echanisms of action. In the case of SMs, a limitation of
emodeling is not supported by the lack of between-group
ifferences in diastolic function. It is therefore more likely
hat engrafted myoblasts provided added systolic function,
ither directly through direct transmembrane electrotonic
urrents fired by neighboring cardiomyocytes or indirectly
hrough paracrine mechanisms (20). Protection of sur-
ounding host cardiomyocytes by such a release of soluble
actors or cell-cell interactions is most likely the predomi-
ant mechanism of operation after CD133 cell transplan-ation to account for the functional improvement persisting
eyond the graft loss. Our failure to demonstrate between-
roup differences in angiogenesis does not exclude a release
f other progenitor-derived cytokines or growth factors that
ould improve function through favorable changes in extra-
ellular matrix remodeling, rescue of reversibly damaged
ost cardiomyocytes, or recruitment of a resident pool of
ardiac stem cells (21). Indeed, a similar discrepancy be-
ween the loss of engrafted human umbilical vein endothe-
ial cells over the course of time and a sustained improve-
ent in function recently has been reported in a rat model
f myocardial infarction (22) and supports the paradigm of
ong-lasting cell-mediated paracrine effects that could re-
ain operative even when the original graft is no longer
etectable. This hypothesis is indirectly supported by our
ndings that CD133 cells can still be detected when hearts
re examined at an earlier time point (six days) after
ransplantation (data not shown).
onclusions. The CD133 hematopoietic progenitors ef-
ectively preserve postinfarction LV function although, in
he setting of fibrous scars, their functional efficacy does not
eem to be greater than that of SMs, which may represent
benchmark against which alternate cell types should be
ested.
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erm U633, Laboratoire d’e´tude des greffes et prothe`ses car-
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